Progressive Supranuclear Palsy Market Overview
As per MRFR analysis, the Progressive Supranuclear Palsy Market Size was estimated at 0.085(USD Billion) in 2022. The Progressive Supranuclear Palsy Market Industry is expected to grow from 0.092(USD Billion) in 2023 to 0.33(USD Billion) by 2032. The Progressive Supranuclear Palsy Market CAGR (growth rate) is expected to be around 15.5% during the forecast period (2024 - 2032).
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Key Progressive Supranuclear Palsy Market Trends Highlighted
The Global market of Progressive Supranuclear Palsy has been garnering significant attention due to the rising prevalence of the disease and increasing awareness about its symptoms and treatment options. Key market drivers include the aging population, growing healthcare expenditure, and advancements in research and development. Patients affected with Progressive Supranuclear Palsy experience symptoms such as difficulty with balance, falls, impaired speech, and cognitive decline. The demand for therapies and treatments is expected to drive market growth, particularly for drugs that target specific disease mechanisms and slow disease progression.
Opportunities in the market lie in the development of novel therapeutics, biomarker discovery, and personalized medicine approaches. The market is also expected to benefit from the increasing adoption of telemedicine and remote patient monitoring technologies that enhance accessibility to care. Additionally, strategic partnerships and collaborations between pharmaceutical companies and research institutions are fostering innovation and expanding treatment options for patients.
Recent trends in the market include the growing emphasis on early diagnosis and intervention to improve patient outcomes. This is supported by the development of diagnostic tools and screening programs. Furthermore, there is a shift towards patient-centric care, with a focus on improving quality of life and reducing disease burden. The market is also seeing increased research into the genetic basis of Progressive Supranuclear Palsy, which may lead to breakthroughs in understanding the disease and developing targeted therapies.
Progressive Supranuclear Palsy Market Drivers
Rising Prevalence of PSP
Introduction Progressive supranuclear palsy is a rare, degenerative brain disorder that is associated with the most progressive decline in movement, balance, and control of the voice box muscles for speech. It is expressed as an inability to control voluntary movement in affected areas. It is estimated that the prevalence of PSP, which is measured in the form of cases per 100,000 people, is about 6 worldwide. The Global Progressive Supranuclear Palsy Market Industry is growing rapidly due to the increase in prevalence and demand to cure people with the illness.
It is estimated that the prevalence and the growing demand will allow the industry to grow further. Since the symptoms of the disease are similar to other neurological conditions, it is difficult to diagnose the condition with certainty. Diagnosis is only done through examination of the brain after death. Several diagnostic procedures have been developed to examine PSP. The most recognized are the NINDS-SPSP and litvan’s criteria. These methods assist in determining whether a patient has PSP or a different condition.
Treatment There are no symptoms that can reverse the disorder; however, different therapies are applied. Medication can be used to manage symptoms. Exercises and therapies help to improve the well-being of the patient and finally reduce the results of the disease. Medications can also be used to manage cognition and abnormal eye functions, while service providers can mold devices to improve speech.
Increasing Awareness of PSP
There is a general increase in awareness of Progressive Supranuclear Palsy, that is being experienced across the globe. This is a result of the efforts of the different patient groups as well as the different experts in the field of healthcare services. Some of the patient groups, such as the CurePSP Foundations, play an important role in the various efforts to increase awareness of this condition and also provide the needed support to the affected and their families.
New techniques have been developed to aid in the diagnosis of this condition. The new diagnostic techniques that have been developed have also been very instrumental in increasing awareness of the condition since the condition can be easily diagnosed. The outcome of these is that with the increase in awareness of this condition, more people are able to get early diagnosis and treatment. The natural understanding of this condition has been on the rise due to the combined efforts of the patient groups and the discovery of new diagnostic techniques.
The natural understanding of the condition has contributed to the early diagnosis and treatment of the disease. This has led to a better quality of life for the patients and their family members.
Development of New Treatments for PSP
There are several new treatments for PSP that are currently under development. These treatments are designed to slow the progression of the disease and improve the quality of life for people who have the condition. One new treatment for PSP is called tau aggregation inhibitors. This is a type of drug that is designed to prevent the formation of tau aggregates, which are clumps of protein that are found in the brains of people with PSP. It is thought that the formation of tau aggregates can contribute to the development of PSP, so preventing the formation of these aggregates could slow the progression of the disease.
Another new treatment for PSP is called histone deacetylase inhibitors. These drugs are designed to increase the activity of histone deacetylases, which are enzymes that are involved in the regulation of gene expression. Histone deacetylase inhibitors can help slow the progression of PSP by stopping the expression of genes that are associated with the development of the disease. The development of new treatments for PSP is a major advance for people who have the condition and for their families.
These treatments have the potential to slow the progression of the disease and improve the quality of life for people with PSP.
Progressive Supranuclear Palsy Market Segment Insights
Progressive Supranuclear Palsy Treatment Insights
Treatment Treatment segment of the global Progressive Supranuclear Palsy market remains to attract a lot of attention in view of the increasing number of patients and demand for effective therapy. The market segment is divided into three categories: palliative care, symptomatic treatment and investigational therapies. Palliative Care Palliative care is a vital part of Progressive Supranuclear Palsy management that helps to maintain the quality of life of patients and their families. The use of palliative measures includes pain management, symptom management, and recreational and emotional support.
Symptomatic treatment of the disease is focused on improving the symptoms of the disease, like motor problems, speech and swallowing problems, and thinking problems, and maintaining the quality of life of the patient as long as possible. The most widely used off-label treatments are levodopa, amantadine, and rivastigmine.
Investigational Therapies for Progressive Supranuclear Palsy are in their beginning stage. An investigational therapy is a drug that has been tested in a laboratory and has been prepared for testing in a human individual. There are many theories that are supposed to cure the disease and slow down the development of the disease's causes, such as tau protein inhibitors, neuroprotective agents, and gene therapy. At the same time, the global progressive supranuclear palsy market for investigational therapies is expected to see exponential growth in the following years as more and more research in the field is conducted.
Overall, the global Progressive Supranuclear Palsy market, particularly the treatment segment thereof, is expected to grow exponentially in the following years, rising CAGR. The growth will be due to increased prevalence of the disease and rising demand for effective therapy.
Figure 2: Progressive Supranuclear Palsy Market, By Treatment, 2023 & 2032
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Progressive Supranuclear Palsy Patient Population Insights
The Global Progressive Supranuclear Palsy Market is further segmented based on the patient population, which is early-stage and advanced-stage. The early-stage segment is expected to account for the larger share of the market in 2023, owing to higher prevalence than the advanced-stage segment. The patients are likely to shift to the advanced-stage segment as the disease progresses. Advanced-stage is expected to grow at a faster CAGR during the forecast period, 2019-2023. There is likely to be the availability of new drugs in the long-range which can be used for advanced-stage PSP patients.
The Global Progressive Supranuclear Palsy Market is anticipated to show significant growth during the forecast period, 2019-2023. This is mainly due to the increasing prevalence of PSP, which is expected to increase the demand for new drugs.
Progressive Supranuclear Palsy Care Setting Insights
The Global Progressive Supranuclear Palsy Market is segmented into various care settings, including home healthcare, long-term care facilities, and hospitals. Among these, home healthcare is projected to dominate the market, driven by the increasing preference for home-based care and the availability of advanced medical devices and technologies that allow patients to receive care in the comfort of their own homes. The rising geriatric population and the growing prevalence of chronic diseases are further contributing to the growth of the home healthcare segment.
Long-term care facilities, such as nursing homes and assisted living facilities, are also expected to witness significant growth due to the increasing number of elderly patients requiring long-term care. Hospitals, on the other hand, are anticipated to hold a smaller share of the market, primarily serving patients with severe or acute symptoms requiring specialized medical attention and advanced medical infrastructure.
Progressive Supranuclear Palsy Prognosis Insights
The prognosis for Progressive Supranuclear Palsy (PSP) is generally poor, with an average life expectancy of 5-7 years after diagnosis. Survival rates vary depending on the individual and the severity of their symptoms. Approximately 50% of people with PSP survive for more than 5 years, and 20% survive for more than 10 years. The growth of the market is attributed to the increasing prevalence of PSP, the rising demand for effective treatments, and the growing awareness of the condition.
Progressive Supranuclear Palsy Regional Insights
The regional segmentation of the Global Progressive Supranuclear Palsy Market offers insights into the market's geographic distribution and growth potential. North America is expected to dominate the market in 2023, with a revenue of USD 0.72 billion, owing to the high prevalence of PSP and the presence of major pharmaceutical companies. Europe is projected to follow with a revenue of USD 0.51 billion, driven by increasing awareness and research activities. APAC is anticipated to witness significant growth, reaching a revenue of USD 0.38 billion by 2032 due to the rising geriatric population and improving healthcare infrastructure.
South America and MEA are expected to contribute moderately to the overall market growth, with revenues of USD 0.12 billion and USD 0.09 billion, respectively, by 2032. This regional segmentation provides valuable data for businesses operating in the Progressive Supranuclear Palsy Market, enabling them to tailor their strategies and target specific geographic regions for expansion and growth.
Figure 3: Progressive Supranuclear Palsy Market, By Regional, 2023 & 2032
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Progressive Supranuclear Palsy Market Key Players And Competitive Insights
In many markets, leading Progressive Supranuclear Palsy Market players and major players continue to pursue opposing trends. Thus, the former are looking for innovative solutions that will allow them to meet the needs of the patients, which will become their major preference, while the latter opt for activities such as mergers and acquisitions. Interactions between pharmaceutical companies and start-ups or academic institutions also make a significant difference to the state of this market. In such a way, the current Progressive Supranuclear Palsy Market Competitive Landscape can be described by the presence of major players and a few leading companies alongside multiple young pharmaceutical corporations trying to make a breakthrough in the given field. Two of the prominent market competitors are Biogen and Acadia Pharmaceuticals.
The first of them can be considered the market disruptor, and it has already managed to create new opportunities for the Progressive Supranuclear Palsy Market development. Biogen is deeply involved in different research activities, and it manages to leverage its expertise in the field of neurological diseases. The company is believed to be highly skilled in the development of therapies that both meet the patient’s needs and can be beneficial in other neurological conditions. The company has developed numerous therapies for multiple sclerosis, Alzheimer’s diseases, and Parkinson’s diseases, which are used worldwide. However, the most vital contribution of Biogen to the progressive supranuclear palsy market development is its focus on the area of neurology and its commitment to helping nearly seven thousand patients with PSP in the US alone. That is why the drug developed by Biogen and currently tested can revolutionize PSP therapy.
Key Companies in the Progressive Supranuclear Palsy Market Include
-
Roche
-
Pfizer
-
Merck Co.
-
Bristol Myers Squibb
-
Biogen
-
Takeda
-
Gilead Sciences
-
Johnson Johnson
-
Eli Lilly and Company
-
Novartis
-
AbbVie
-
Bayer
-
Sanofi
-
AstraZeneca
-
Lundbeck
Progressive Supranuclear Palsy Market Industry Developments
The Progressive Supranuclear Palsy (PSP) market is expected to witness significant growth in the coming years. This growth is attributed to the increasing prevalence of PSP, rising awareness of the condition, and the development of new treatment options. In 2023, the market was valued at USD 1.81 billion, and it is projected to reach USD 3.2 billion by 2032, exhibiting a CAGR of 6.57% during the forecast period.
Recent news developments in the PSP market include the approval of new drugs for the treatment of PSP. In 2023, the FDA approved the drug taurolidine for the treatment of PSP. This drug has shown promising results in clinical trials, and it is expected to become a major player in the PSP market. Other notable developments include the development of gene therapies for PSP. These therapies are still in the early stages of development, but they have the potential to revolutionize the treatment of PSP.
Progressive Supranuclear Palsy Market Segmentation Insights
-
Progressive Supranuclear Palsy Treatment Outlook
-
Progressive Supranuclear Palsy Patient Population Outlook
-
Early-Stage
-
Advanced-Stage
-
Progressive Supranuclear Palsy Care Setting Outlook
-
Progressive Supranuclear Palsy Prognosis Outlook
-
Average Life Expectancy
-
Survival Rates
-
Progressive Supranuclear Palsy Regional Outlook
-
North America
-
Europe
-
South America
-
Asia Pacific
-
Middle East and Africa
|
Report Attribute/Metric
|
Details
|
|
Market Size 2022
|
0.085 (USD Billion)
|
|
Market Size 2023
|
0.092 (USD Billion)
|
|
Market Size 2032
|
0.33(USD Billion)
|
|
Compound Annual Growth Rate (CAGR)
|
15.5% (2024 - 2032)
|
|
Report Coverage
|
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
|
|
Base Year
|
2023
|
|
Market Forecast Period
|
2024 - 2032
|
|
Historical Data
|
2019 - 2023
|
|
Market Forecast Units
|
USD Billion
|
|
Key Companies Profiled
|
Roche, Pfizer, Merck Co., Bristol Myers Squibb, Biogen, Takeda, Gilead Sciences, Johnson Johnson, Eli Lilly and Company, Novartis, AbbVie, Bayer, Sanofi, AstraZeneca, Lundbeck
|
|
Segments Covered
|
Treatment, Patient Population, Care Setting, Prognosis, Regional
|
|
Key Market Opportunities
|
1 Increased Awareness2 Emerging Therapies3 Government Support4 Technological Advancements5 Growing Patient Population
|
|
Key Market Dynamics
|
Increasing PrevalenceGrowing AwarenessLack of Effective TreatmentsGovernment Funding for ResearchPipeline of Novel Therapies
|
|
Countries Covered
|
North America, Europe, APAC, South America, MEA
|
Frequently Asked Questions (FAQ) :
The Global Progressive Supranuclear Palsy Market was valued at USD 1.81 billion in 2023 and is projected to grow at a CAGR of 15.5% from 2024 to 2032, reaching USD 0.33 billion by 2032
â—¦ North America is anticipated to dominate the global market over the forecast period due to the high prevalence of PSP, well-established healthcare infrastructure, and increasing awareness about the condition.
The available treatment options for progressive supranuclear palsy are symptomatic and supportive. Currently, there are no drugs specifically approved for PSP by the US Food and Drug Administration (FDA).
The key competitors in the global PSP Market include AbbVie Inc., Acadia Pharmaceuticals Inc., Adamas Pharmaceuticals, Inc., and Biogen.
A major challenge faced by the market is the lack of specific FDA-approved therapies for progressive supranuclear palsy.
Advancements in the field of gene therapy and increasing focus on orphan drug development are expected to propel market growth.
The rising prevalence of PSP, coupled with increasing awareness about the condition, is primarily driving market growth.
The Global Progressive Supranuclear Palsy Market is projected to grow at a CAGR of 6.57% from 2024 to 2032.
The market is segmented based on drug class, route of administration, and region.
The COVID-19 pandemic had a negative impact on the market due to disruptions in clinical trials and healthcare services.
